Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | F11 | P03951 | 2/20 | 0.34 |
| ▸ | PTPRB | P23467 | 2/20 | 0.34 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.33 |
| ▸ | DUSP10 | Q9Y6W6 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.33 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.33 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.33 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.33 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.33 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.33 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.33 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.33 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.33 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4519491 | 0.91 | MAP4K4 (0.37) | PAX8MAPTTDP1 | |
| SCHEMBL4530317 | 0.90 | MAPT (0.35) | MAPTALDH1A1POLB | |
| SCHEMBL4532204 | 0.83 | CIT (0.42) | PAX8F11GPR142DUSP10PDK1 | |
| SCHEMBL4528518 | 0.79 | CTSS (0.39) | SLC7A5ITGA4ITGB7 | |
| SCHEMBL4382719 | 0.78 | JAK2 (0.55) | CIT | |
| SCHEMBL4377164 | 0.78 | JAK2 (0.55) | CIT | |
| SCHEMBL4514249 | 0.76 | ROCK2 (0.37) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL4519488 | 0.74 | MAP4K4 (0.36) | PAX8CITMAPT | |
| SCHEMBL4516346 | 0.74 | SYK (0.36) | PAX8DUSP10MAPTALDH1A1POLB | |
| SCHEMBL4529962 | 0.74 | HDAC8 (0.52) | PTPRBCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1922306-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007026920-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | PAX8 3961/4885F11 2603/4885PTPRB 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.